<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Oxycodone - Complete Profile</title>
    <link rel="stylesheet" href="/style.css">
</head>

<body>
  <body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/" class="site-title">Dyo's Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/">Home</a>
          </li>
          <li>
            <a href="/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/about/">About</a>
          </li>
          <li>
            <a href="/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/depressants/">Depressants</a> ‚Üí <span>Oxycodone</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üíä Oxycodone</h1>
        <h2 class="chemical-name">4,5Œ±-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one</h2>
          <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Oxycodone" 
                data-category="Depressants" 
                data-chemical="4,5Œ±-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>OxyContin</span> ‚Ä¢ <span>Percocet</span> ‚Ä¢ <span>Endocet</span> ‚Ä¢ <span>Roxicodone</span> ‚Ä¢ <span>Percodan</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Oxy</span> ‚Ä¢ <span>OC</span> ‚Ä¢ <span>Oxycotton</span> ‚Ä¢ <span>Hillbilly Heroin</span> ‚Ä¢ <span>Blues</span>
            </div>
            <div class="name-category">
              <h4>Pill Names</h4>
              <span>80s</span> ‚Ä¢ <span>40s</span> ‚Ä¢ <span>Roxies</span> ‚Ä¢ <span>Percs</span> ‚Ä¢ <span>Pills</span>
            </div>
            <div class="name-category">
              <h4>Chemical</h4>
              <span>Oxycodone HCl</span> ‚Ä¢ <span>14-Hydroxydihydrocodeinone</span> ‚Ä¢ <span>Dihydrohydroxycodeinone</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category prescription addiction-risk">Prescription Opioid</span>
          <span class="legal-status schedule-2">Schedule II</span>
          <span class="duration medium">4-6 hours (IR) / 12 hours (ER)</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/oxycodone.jpg" alt="Various oxycodone pills including OxyContin tablets, Percocet, and Roxicodone, showing different colors and imprints" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇàH‚ÇÇ‚ÇÅNO‚ÇÑ</p>
            <p>MW: 315.36 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pharmaceutical Forms</h4>
          <ul>
            <li><strong>Immediate Release (IR):</strong> Round tablets, various colors (white, blue, green, pink, yellow)</li>
            <li><strong>Extended Release (OxyContin):</strong> Round, film-coated tablets with "OP" imprint</li>
            <li><strong>Combination Products:</strong> Percocet (with acetaminophen), Percodan (with aspirin)</li>
            <li><strong>Liquid Forms:</strong> Oral solution (5mg/5mL), concentrated solution (100mg/5mL)</li>
            <li><strong>Injectable:</strong> Hospital use only, clear sterile solution</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Common Pill Identifications</h4>
          <ul>
            <li><strong>OxyContin OP 10:</strong> White, round, 10mg extended-release</li>
            <li><strong>OxyContin OP 20:</strong> Pink, round, 20mg extended-release</li>
            <li><strong>OxyContin OP 40:</strong> Yellow, round, 40mg extended-release</li>
            <li><strong>OxyContin OP 80:</strong> Green, round, 80mg extended-release</li>
            <li><strong>Roxicodone (blue):</strong> Blue, round, 30mg immediate-release ("Blues")</li>
            <li><strong>Percocet 10/325:</strong> Yellow, oval, 10mg oxy + 325mg acetaminophen</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Counterfeit Concerns</h4>
          <p><strong>Fake Pills:</strong> Counterfeit oxycodone pills containing fentanyl are extremely common</p>
          <p><strong>Street Purchases:</strong> Any non-pharmaceutical source carries extreme overdose risk</p>
          <p><strong>Visual Inspection:</strong> Authentic pills have precise imprints, consistent color, proper coating</p>
          <p><strong>Testing:</strong> Fentanyl test strips essential for any street-sourced pills</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">2.5-5mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">5-10mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">10-20mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">20-40mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">40mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Medical Dosing</h4>
        <ul>
          <li><strong>Pain Management:</strong> 5-15mg every 4-6 hours as needed</li>
          <li><strong>OxyContin (ER):</strong> 10mg every 12 hours, titrated to effect</li>
          <li><strong>Opioid-naive patients:</strong> Start with 5mg or less</li>
          <li><strong>Chronic pain:</strong> Requires careful titration by physician</li>
          <li><strong>Elderly/debilitated:</strong> Reduce initial dose by 33-50%</li>
        </ul>
        
        <h4>‚ö†Ô∏è Critical Dosage Warnings</h4>
        <ul>
          <li><strong>Tolerance builds rapidly:</strong> Addiction risk increases with dose escalation</li>
          <li><strong>Respiratory depression:</strong> Life-threatening above tolerance level</li>
          <li><strong>Never crush extended-release:</strong> Can cause fatal overdose</li>
          <li><strong>Acetaminophen combinations:</strong> Max 3000mg acetaminophen per day</li>
          <li><strong>Cross-tolerance:</strong> Tolerance to other opioids affects dosing</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Overdose Risk:</strong> Even therapeutic doses can be fatal in opioid-naive individuals. Counterfeit pills containing fentanyl have caused thousands of deaths.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Immediate Release)</h4>
        <div class="timeline-item">
          <span class="time">T+0:15-0:30</span>
          <span class="effect">Onset - pain relief, mild euphoria</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:00-2:00</span>
          <span class="effect">Peak - maximum analgesia and euphoria</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+3:00-6:00</span>
          <span class="effect">Duration - sustained pain relief</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+6:00+</span>
          <span class="effect">Comedown - pain returns, possible withdrawal</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category therapeutic">
          <h4>‚úÖ Therapeutic Effects</h4>
          <ul>
            <li>Powerful analgesia (pain relief)</li>
            <li>Euphoria and mood elevation</li>
            <li>Anxiety reduction</li>
            <li>Cough suppression</li>
            <li>Sedation and relaxation</li>
            <li>Emotional numbing</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Adverse Effects</h4>
          <ul>
            <li>Respiratory depression</li>
            <li>Severe constipation</li>
            <li>Nausea and vomiting</li>
            <li>Drowsiness and cognitive impairment</li>
            <li>Physical dependence</li>
            <li>Withdrawal syndrome</li>
          </ul>
        </div>
        
        <div class="effect-category overdose">
          <h4>üö® Overdose Signs</h4>
          <ul>
            <li>Slow, shallow breathing (&lt;12 breaths/min)</li>
            <li>Blue lips, fingernails, or skin</li>
            <li>Cold, clammy skin</li>
            <li>Weak pulse</li>
            <li>Loss of consciousness</li>
            <li>Gurgling or choking sounds</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Oxycodone is a semi-synthetic opioid that acts as a potent agonist at Œº-opioid receptors (MOR), with additional activity at Œ∫-opioid and Œ¥-opioid receptors. It binds to opioid receptors in the brain, spinal cord, and peripheral tissues, mimicking endogenous opioids like endorphins. This activation inhibits adenylyl cyclase, reduces cAMP levels, and ultimately decreases neuronal excitability and neurotransmitter release.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œº-opioid receptor (MOR)</strong></span>
            <span class="affinity">High affinity agonist (Ki: ~20 nM)</span>
            <span class="function">Primary analgesia, euphoria, respiratory depression</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ∫-opioid receptor (KOR)</strong></span>
            <span class="affinity">Moderate affinity agonist</span>
            <span class="function">Analgesia, dysphoria, reduced abuse potential</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ¥-opioid receptor (DOR)</strong></span>
            <span class="affinity">Low-moderate affinity</span>
            <span class="function">Analgesia, mood effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NMDA receptor</strong></span>
            <span class="affinity">Weak antagonist activity</span>
            <span class="function">May contribute to analgesic effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Norepinephrine transporter</strong></span>
            <span class="affinity">Weak inhibition</span>
            <span class="function">May contribute to analgesic synergy</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> N-demethylation by CYP3A4 ‚Üí noroxycodone (less active)</p>
          <p><strong>Secondary Pathway:</strong> O-demethylation by CYP2D6 ‚Üí oxymorphone (highly active)</p>
          <p><strong>Half-life:</strong> 3-5 hours (IR), 4-6 hours (ER)</p>
          <p><strong>Bioavailability:</strong> 60-87% oral (higher than morphine)</p>
          <p><strong>Peak plasma:</strong> 1-1.5 hours (IR), 3 hours (ER)</p>
          <p><strong>Protein binding:</strong> ~45% (moderate)</p>
          <p><strong>Active metabolites:</strong> Oxymorphone (2-3x more potent than oxycodone)</p>
        </div>

        <h4>Abuse-Deterrent Technology</h4>
        <div class="abuse-deterrent-info">
          <p><strong>Original OxyContin:</strong> Could be crushed and snorted/injected (discontinued 2010)</p>
          <p><strong>Current OP formulation:</strong> Forms gel when crushed, resists extraction</p>
          <p><strong>Tamper resistance:</strong> Polymer matrix prevents easy manipulation</p>
          <p><strong>Effectiveness:</strong> Reduced but did not eliminate abuse potential</p>
          <p><strong>Unintended consequences:</strong> May have driven users to heroin and fentanyl</p>
        </div>

        <h4>Tolerance and Dependence</h4>
        <div class="dependence-info">
          <p><strong>Physical dependence:</strong> Can develop within days of regular use</p>
          <p><strong>Tolerance mechanisms:</strong> Receptor downregulation, desensitization</p>
          <p><strong>Cross-tolerance:</strong> Complete with other opioids</p>
          <p><strong>Withdrawal timeline:</strong> Onset 6-12 hours, peak 72 hours, duration 5-10 days</p>
          <p><strong>Psychological dependence:</strong> High addiction potential due to euphoric effects</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>High oral bioavailability:</strong> More effective orally than morphine</li>
          <li><strong>Dual metabolism:</strong> Both active and inactive metabolite pathways</li>
          <li><strong>CNS penetration:</strong> Crosses blood-brain barrier more readily than morphine</li>
          <li><strong>Potency:</strong> ~1.5x more potent than morphine orally</li>
          <li><strong>Duration:</strong> Longer-acting than immediate-release morphine</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Respiratory depression:</strong> Can be fatal, especially with alcohol</li>
            <li><strong>Rapid addiction:</strong> Physical dependence within days</li>
            <li><strong>Counterfeit pills:</strong> Street pills often contain lethal fentanyl</li>
            <li><strong>Withdrawal:</strong> Can be severe and requires medical supervision</li>
            <li><strong>Tolerance:</strong> Rapidly escalating doses increase overdose risk</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Harm Reduction</h4>
          <ul>
            <li>Never obtain from non-medical sources</li>
            <li>Take exactly as prescribed by physician</li>
            <li>Never crush or chew extended-release formulations</li>
            <li>Avoid alcohol and benzodiazepines</li>
            <li>Have naloxone (Narcan) available</li>
            <li>Never use alone - have someone present</li>
            <li>Start low if switching from other opioids</li>
          </ul>
        </div>
      </div>

      <div class="overdose-response">
        <h4>üöë Overdose Response</h4>
        <p><strong>Call 911 immediately.</strong> Administer naloxone if available. Perform rescue breathing. Turn person on side to prevent choking. Stay with person until help arrives. Naloxone may need repeated doses as oxycodone has a longer duration.</p>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Respiratory depression, severe asthma, paralytic ileus, known hypersensitivity. Use extreme caution with: head injuries, liver/kidney disease, elderly patients, pregnancy/breastfeeding.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Potentially Fatal</h4>
          <ul>
            <li><strong>Alcohol:</strong> Extreme respiratory depression risk</li>
            <li><strong>Benzodiazepines:</strong> Synergistic CNS depression, high overdose risk</li>
            <li><strong>Barbiturates:</strong> Additive respiratory depression</li>
            <li><strong>Muscle relaxants:</strong> Enhanced sedation and respiratory depression</li>
            <li><strong>Sleep medications:</strong> Dangerous CNS depression</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° High Risk</h4>
          <ul>
            <li><strong>CYP3A4 inhibitors:</strong> Ketoconazole, erythromycin increase levels</li>
            <li><strong>CYP3A4 inducers:</strong> Rifampin decreases effectiveness</li>
            <li><strong>MAOIs:</strong> Risk of serotonin syndrome with some combinations</li>
            <li><strong>Anticholinergics:</strong> Increased constipation, urinary retention</li>
          </ul>
        </div>
        
        <div class="interaction moderate">
          <h4>üü† Moderate Risk</h4>
          <ul>
            <li><strong>Antihistamines:</strong> Increased sedation</li>
            <li><strong>Gabapentinoids:</strong> Enhanced CNS depression</li>
            <li><strong>Antidepressants:</strong> Potential serotonin effects</li>
            <li><strong>Beta-blockers:</strong> May mask overdose symptoms</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Schedule II</strong> - Legal by prescription only. High potential for abuse leading to severe psychological or physical dependence. Strict prescribing regulations under DEA oversight.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Schedule I (Class A)</strong> - Controlled drug, prescription only. Illegal possession without prescription carries up to 7 years imprisonment.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá®üá¶ Canada</h4>
            <p><strong>Schedule I</strong> - Controlled substance, prescription required. Part of national opioid crisis response efforts.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¶üá∫ Australia</h4>
            <p><strong>Schedule 8</strong> - Controlled drug, restricted availability. Requires special prescribing authority in some states.</p>
          </div>
        </div>
        
        <div class="prescription-regulations">
          <h4>üè• Prescription Regulations</h4>
          <p><strong>US Requirements:</strong> DEA registration required for prescribers. No refills allowed - new prescription required each time. Must be written on tamper-proof prescription pads. Electronic prescribing increasingly mandated.</p>
          <p><strong>Monitoring Programs:</strong> Prescription Drug Monitoring Programs (PDMPs) track all opioid prescriptions to prevent doctor shopping and identify potential abuse.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Cultural Impact</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1916</span>
          <p>First synthesized in Germany from thebaine (opium alkaloid)</p>
        </div>
        <div class="history-event">
          <span class="year">1939</span>
          <p>First clinical use as analgesic in Germany</p>
        </div>
        <div class="history-event">
          <span class="year">1950s</span>
          <p>Introduced to US market for cancer pain management</p>
        </div>
        <div class="history-event">
          <span class="year">1995</span>
          <p>OxyContin launched by Purdue Pharma with aggressive marketing</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>Prescription opioid epidemic begins, OxyContin abuse skyrockets</p>
        </div>
        <div class="history-event">
          <span class="year">2010</span>
          <p>Abuse-deterrent OP formulation introduced</p>
        </div>
        <div class="history-event">
          <span class="year">2019</span>
          <p>Purdue Pharma files bankruptcy amid thousands of lawsuits</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>The OxyContin Crisis</h4>
        <p>OxyContin became the focal point of America's opioid epidemic. Purdue Pharma's deceptive marketing claimed the drug was "virtually non-addictive" and suitable for moderate pain. This led to massive overprescribing, widespread addiction, and a health crisis that killed over 500,000 Americans. The introduction of abuse-deterrent formulations inadvertently drove many users to heroin and fentanyl, worsening the crisis.</p>
        
        <h4>Legal and Social Consequences</h4>
        <p>The oxycodone crisis resulted in thousands of lawsuits against Purdue Pharma and the Sackler family, ultimately leading to a $4.5 billion settlement. It fundamentally changed pain management practices, led to stricter prescribing guidelines, and highlighted the dangers of pharmaceutical marketing manipulation.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research & Medical Use</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Pain Management</h4>
          <p>Oxycodone remains valuable for severe acute pain (post-surgical, trauma) and cancer pain when used appropriately. Research focuses on optimal dosing strategies and duration limits to minimize addiction risk.</p>
        </div>
        
        <div class="research-item">
          <h4>Abuse-Deterrent Formulations</h4>
          <p>Ongoing development of new tamper-resistant technologies including agonist-antagonist combinations, prodrug formulations, and abuse-deterrent delivery systems.</p>
        </div>
        
        <div class="research-item">
          <h4>Addiction Treatment</h4>
          <p>Research into medication-assisted treatment (MAT) using buprenorphine, methadone, and naltrexone for oxycodone addiction. Extended-release naltrexone shows promise for preventing relapse.</p>
        </div>
        
        <div class="research-item">
          <h4>Alternative Pain Therapies</h4>
          <p>Development of non-opioid pain medications, regional anesthesia techniques, and multimodal pain management approaches to reduce opioid dependence in medical settings.</p>
        </div>
      </div>

      <div class="addiction-treatment">
        <h4>üè• Addiction Treatment Approaches</h4>
        <div class="treatment-options">
          <div class="treatment-option">
            <h5>Medication-Assisted Treatment (MAT)</h5>
            <ul>
              <li><strong>Buprenorphine:</strong> Partial opioid agonist, reduces cravings</li>
              <li><strong>Methadone:</strong> Full opioid agonist, daily clinic visits</li>
              <li><strong>Naltrexone:</strong> Opioid antagonist, blocks euphoric effects</li>
            </ul>
          </div>
          
          <div class="treatment-option">
            <h5>Behavioral Therapies</h5>
            <ul>
              <li><strong>Cognitive Behavioral Therapy (CBT)</strong></li>
              <li><strong>Contingency Management</strong></li>
              <li><strong>12-Step Programs</strong></li>
              <li><strong>SMART Recovery</strong></li>
            </ul>
          </div>
          
          <div class="treatment-option">
            <h5>Medical Detoxification</h5>
            <ul>
              <li><strong>Inpatient detox:</strong> Medical supervision for severe withdrawal</li>
              <li><strong>Comfort medications:</strong> Clonidine, loperamide, NSAIDs</li>
              <li><strong>Rapid detox:</strong> Controversial, high-risk procedures</li>
            </ul>
          </div>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Crisis & Emergency</h4>
        <ul>
          <li><a href="https://www.samhsa.gov/find-help/national-helpline">SAMHSA National Helpline</a> - 24/7 treatment referral</li>
          <li><a href="https://www.cdc.gov/opioids/basics/epidemic.html">CDC Opioid Information</a> - Epidemic statistics and resources</li>
          <li><a href="https://www.naloxoneforall.org/">Naloxone for All</a> - Overdose reversal information</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Treatment Resources</h4>
        <ul>
          <li><a href="https://www.samhsa.gov/medication-assisted-treatment">SAMHSA MAT</a> - Medication-assisted treatment locator</li>
          <li><a href="https://www.smartrecovery.org/">SMART Recovery</a> - Science-based addiction recovery</li>
          <li><a href="https://www.na.org/">Narcotics Anonymous</a> - Peer support meetings</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Educational Resources</h4>
        <ul>
          <li><a href="https://www.deadiversion.usdoj.gov/">DEA Diversion Control</a> - Legal and safety information</li>
          <li><a href="https://www.cdc.gov/drugoverdose/">CDC Drug Overdose</a> - Prevention and data</li>
          <li><a href="https://www.drugabuse.gov/drug-topics/opioids">NIDA Opioids</a> - Scientific research and education</li>
        </ul>
      </div>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/js/lunr.min.js"></script>
    <script src="/assets/js/search.js"></script>
    <script src="/assets/js/substance-integration.js"></script>
</body>
</html>